WS #16349
Moderna has tumbled 20% and Merck is sliding following reports that Phase 3 data for their experimental melanoma vaccine was leaked prematurely. The leak has created significant uncertainty regarding the efficacy and regulatory timeline of the asset, causing a sharp repricing of biotech risk. This development dampens the bullish thesis for the broader oncology pipeline sector as investors reassess the reliability of clinical data disclosure.
Biotech Vaccine Data Leak
Moderna has tumbled 20% and Merck is sliding following reports that Phase 3 data for their experimental melanoma vaccine was leaked prematurely. The leak has created significant uncertainty regarding the efficacy and regulatory timeline of the asset, causing a sharp repricing of biotech risk. This development dampens the bullish thesis for the broader oncology pipeline sector as investors reassess the reliability of clinical data disclosure.